MetaCap

Nektar Therapeutics (NKTR)

NASDAQ: NKTRHealth CareBiotechnology: Pharmaceutical PreparationsUSD

30.20-2.34 (-7.19%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NKTR stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$22.47
52-week range
30.13 – 109.00
Day range
30.13 – 32.35
Volume / Avg
1.02M / 1.12M
Beta
—

52-week range

$30.13$109.00

NKTR stock today

Shares of Nektar Therapeutics (NKTR) finished lower on Nov 20 at $30.20, a drop of 7.19% or $2.34 per share, versus the S&P 500's 3.70% decline. Shares are 72.3% below their 52-week high of $109.00, set on Apr 20, 2026 and 0.2% above the 52-week low of $30.13, near the bottom of the past year's range. NKTR is down 28.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 44.4%.

Nektar Therapeutics has posted a net loss over the last twelve months (EPS of -$22.47), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Nektar Therapeutics

Company profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Howard W. Robin
Headquarters
San Francisco, CA
Employees
63
Website
nektar.com

Financial highlights

Full financials

In fiscal 2025, Nektar Therapeutics generated $55.2 million in revenue, down 43.9% from fiscal 2024, its first annual decline since 2023. Nektar Therapeutics reported a net loss of $164.1 million, compared with a loss of $119.0 million a year earlier. Gross margin was 100.0% (up from 68.8%) and operating margin -253.7%.

Nektar Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$55.23M$98.43M$90.12M$92.06M$101.91M
Growth-43.89%+9.22%-2.10%-9.67%-33.36%
Net income$-164.08M$-118.96M$-276.06M$-368.20M$-523.84M
EPS (diluted)$-9.73$-8.68$-1.45$-1.97$-2.86

Analyst forecast

Forecast

Consensus (15 analysts)

buy

Avg. price target

$131.92+336.82%

  • Strong buy 1
  • Buy 10
  • Hold 4
  • Sell 0
  • Strong sell 0

Target range

Low $40.00High $192.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-1.85 vs $-2.16
Surprise
+14.35%

NKTR news

All NKTR news

Nektar Therapeutics peers

Health Care sector
NKTR peer companies
CompanyPrice% ChgMarket capCompare
CTYCity Therapeutics Inc.19.32+5.29%$1.03Bvs NKTR
ANROAlto Neuroscience Inc.25.37-4.30%$1.02Bvs NKTR
JBIOJade Biosciences Inc.15.31+1.66%$1.06Bvs NKTR
KARDKardigan Inc.11.54-7.83%$1.08Bvs NKTR
OMEROmeros Corporation13.21-5.71%$983.66Mvs NKTR
SPTXSeaport Therapeutics Inc.18.05-1.47%$966.23Mvs NKTR
CYRXCryoPort Inc.19.05-2.56%$964.87Mvs NKTR
AAPGAscentage Pharma Group International American Depository Shares11.97-3.78%$1.12Bvs NKTR

Indexes, lists and sector

Nektar Therapeutics stock FAQ

What is Nektar Therapeutics's stock price today?

NKTR last traded at $30.20 as of Nov 20, 4:00 PM EST, down 7.19% on the day. Prices are delayed at least 15 minutes.

Does Nektar Therapeutics pay a dividend?

No. Nektar Therapeutics does not currently pay a regular cash dividend.

Who is Nektar Therapeutics's CEO?

Mr. Howard W. Robin is the chief executive officer of Nektar Therapeutics, which has about 63 employees.

Has NKTR ever split its stock?

Yes. The most recent NKTR stock split was a 1-for-15 split on Jun 9, 2025, one of 2 splits on record.

What is the NKTR 52-week high?

The 52-week high for NKTR is $109.00 and the 52-week low is $30.13. The stock is currently 72.3% below its high.

Compare NKTR